Amia Capital LLP Incyte Corp Transaction History

Amia Capital LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$80.74 - $97.7 $1.29 Million - $1.56 Million	-15,939 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $327,774 - $422,635	-3,853 Reduced 19.47%	15,939 $1.43 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $730,153 - $1.07 Million	-9,843 Reduced 33.21%	19,792 $2.06 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $655,934 - $892,540	-10,382 Reduced 25.94%	29,635 $2.17 Million
Q4 2019 Feb 13, 2020	BUY	$73.04 - $95.72 $2.92 Million - $3.83 Million	40,017 New	40,017 $3.49 Million

628

198M

766K

476K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Amia Capital LLP, based on Form 13F filings with the SEC.

Stay updated on Amia Capital LLP with notifications on news.